Please contact Scott Hall at firstname.lastname@example.org or 202-463-5817.
Checking in with the Champions: 2017 IP Champions for Excellence in Innovation
Medical breakthroughs and innovations give hope to millions of people, opening new treatment avenues to once untreatable diseases. Research and dedication from the pharmaceutical industry can reach international audiences and impact the lives of millions.
Novartis International, based in Switzerland, has pioneered lifesaving medications for decades through extensive research and development. Just last year, Novartis made a watershed discovery and received the first-ever FDA approval for a CAR-T cell therapy, Kymriah. This new discovery, which treats young adults and children with B-cell precursor acute lymphoblastic leukemia, has proliferated throughout the international medical community.
However, this wouldn’t have been possible without IP. Novartis began collaboration with the University of Pennsylvania in 2012 to further research and develop what would later become Kymriah. This international collaboration resulted from assurances that any new discoveries would be safeguarded in the international community by the IP system – patents, copyrights, and trademarks.
The discovery of Kymriah won Novartis the 2017 IP Champion for Excellence in Innovation Award. This is just one of the many examples of evolutionary approaches in the healthcare sector, and all of them are fueled by IP protections.
IP-intensive innovation is driving the solutions to our biggest global challenges. Whose innovative spirit will inspire you at this year’s IP Champions Gala? Join us on September 12 to honor our 2018 awardees.
Global Innovation Policy Center @globalIPcenter 21h
“[An #IP waiver] would be a destructive policy even if it were necessary, but it is not necessary — it is not even likely to prove beneficial for the purpose at hand, which is helping to speed the pace of global vaccinations.” https://t.co/utPA1XuuqU